Last checked at 31 Jan 2022 11:05
Nuformix plc
("Nuformix" or the "Company")
Result of General Meeting
Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, confirms that, further to the announcement made in connection with the Subscription to raise £1.65 million with Lanstead Capital Investors L.P., at the General Meeting held earlier today all Resolutions were passed by way of a poll, the full results of which are given below:
Resolution | Ordinary/ Special | For | Against | Total votes cast | |||
No. of votes | % | No. of votes | % | ||||
1 | THAT, in addition to existing authorities, the directors are authorised to exercise all powers of the Company to allot new ordinary shares
| Ordinary | 81,448,911 | 95.22% | 4,093,030 | 4.78% | 85,541,941 |
2 | THAT, upon the passing of Resolution 1, the Directors be empowered to allot new ordinary shares for cash on a non-pre-emptive basis.
| Special | 81,438,942 | 95.19% | 4,116,235 | 4.81% | 85,555,177 |
Accordingly, the Company now has sufficient authorities in place to allot the Second Subscription Shares and the Second Value Payment Shares. The Second Subscription remains conditional on there being no requirement for the Company to publish a prospectus in connection with the Second Subscription. It is expected that the Second Subscription Shares and the Second Value Payment Shares will be issued in April 2022 and at that point application will be made to the London Stock Exchange and the Financial Conduct Authority for Admission.
Notes:
1. Any proxy arrangement which gave discretion to the Chairman has been included in the "for" totals.
2. A "Vote withheld" is not a vote in law and is not counted in the calculation of the percentage of shares voted "For" or "Against" any resolution.
3. The number of shares in issue at close of business on 28 January 2022 was 615,609,368. The Company does not hold any shares in treasury.
Unless otherwise defined, all capitalised terms used but not defined in this announcement shall have the meaning given to them in the Circular dated 14 January 2022, a copy of which is available to view on the Company's website (www.nuformix.com).
Enquiries:
Nuformix plc | via Walbrook | ||||
Dr Alastair Riddell, Executive Chairman | |||||
Allenby Capital Limited | +44 (0) 20 3328 5656 | ||||
Nick Athanas / George Payne (Corporate Finance) | |||||
Stefano Aquilino / Matt Butlin (Sales and Corporate Broking) | |||||
Walbrook PR | nuformix@walbrookpr.com or +44 (0)20 7933 8780 | ||||
Anna Dunphy / Phillip Marriage | Tel: +44 (0)7876 741 001 / +44 (0)7867 984 082 | ||||
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase I-ready assets with potential for significant value and early licensing opportunities.